FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:522-524 February 15, 2001 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Hilbert, G. PubMed Citation

Immunocompromised patients with respiratory failure who require mechanical ventilation have notoriously poor prognoses, with mortality rates ranging from 60 to 100 percent, depending on the underlying diagnosis and factors such as age, functional status, the Acute Physiology and Chronic Health Evaluation score, the presence or absence of multiorgan failure, and the duration of neutropenia.¹ Such patients' immunosuppression is most often a consequence of therapy for hematologic cancers, organ transplantation, the acquired immunodeficiency syndrome, or long-term treatment with high doses of corticosteroids. They usually die either from underlying illness or its complications or from the complications of mechanical ventilation.

Although the . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.